Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums).
That doesn’t mean they’re bargains though, and we urge investors to be careful as many have risky business models.
U.S. stocks rallied Thursday after the Trump administration signed its first major trade agreement with the United Kingdom, igniting optimism about further global deals — especially with China — and lifting investor appetite for riskier assets.
Medical supply and logistics company Owens & Minor (NYSE:OMI) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $2.63 billion. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $11 billion at the midpoint. Its non-GAAP profit of $0.23 per share was 14.5% above analysts’ consensus estimates.
What a brutal six months it’s been for Owens & Minor. The stock has dropped 45.6% and now trades at $7.30, rattling many shareholders. This was partly due to its softer quarterly results and might have investors contemplating their next move.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at healthcare distribution & related services stocks, starting with Patterson Companies (NASDAQ:PDCO).
Small-cap stocks in the Russell 2000 can be a goldmine for investors looking beyond the usual large-cap names.
But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 10.2%. This drop was particularly disheartening since the S&P 500 held its ground.
Shares of medical supply and logistics company Owens & Minor (NYSE:OMI) jumped 36.9% in the afternoon session after the company reported impressive fourth quarter 2024 results, exceeding analysts' EBITDA and EPS expectations despite delivering in-line revenue. Full-year revenue guidance was also in line, which is comforting. On the other hand, its full-year EPS guidance fell short of Wall Street's estimates. Overall, the quarter was solid, with strong revenue growth, improving margins, and positive guidance.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Medical supply and logistics company Owens & Minor (NYSE:OMI) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 1.5% year on year to $2.70 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $11 billion at the midpoint. Its non-GAAP profit of $0.55 per share was 5.7% above analysts’ consensus estimates.
Owens & Minor beat Q4 EPS and revenue estimates, announced a $100M buyback, and provided 2025 guidance, projecting double-digit adjusted EBITDA growth.
Shareholders of Owens & Minor would probably like to forget the past six months even happened. The stock has dropped 49.9% and now trades at a new 52-week low of $7.77. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
